Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00273494
Status:
UNKNOWN
Last Update Posted:
2008-05-22
First Post:
2006-01-05
Brief Title:
Neoadjuvant Chemotherapy PlusMinus Surgery in Non-Small-Cell Lung Cancer NSCLC Stage IIIAN2
Sponsor:
Rigshospitalet Denmark
Organization:
Rigshospitalet Denmark
Study Overview
Official Title:
Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIAN2 T1N2 T2N2 T3N2
Status:
UNKNOWN
Status Verified Date:
2008-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease
Patients are randomised to surgery or not
Patients are randomised to surgery or not
Detailed Description:
Patients are after staging randomised to neoadj chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation
Endpoint is survival
Endpoint is survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None